Time course of specific AGEs during optimised glycaemic control in type 2 diabetes

Netherlands Journal of Medicine

Volumn 64, Issue 1, 2006, Pages 10-16

  Mentink, C J A L ^a   Kilhovd, B K ^b   Rondas Colbers, G J W M ^a   Torjesen, P A ^b   Wolffenbuttel, B H R ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Adhesion molecules; AGE; Endothelial dysfunction; Insulin therapy; Methylglyoxal derived hydroimidazolone; N carboxymethyllysine; Type 2 diabetes

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ACETYLSALICYLIC ACID; ADVANCED GLYCATION END PRODUCT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLE DERIVATIVE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; METFORMIN; METHYLGLYOXAL; REACTIVE OXYGEN METABOLITE; SULFONYLUREA;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETES CONTROL; DISEASE DURATION; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED;

EID: 31644435648     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
3. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995;75:894-903.
4. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 2002;288:2579-88.
5. Bucala R, Vlassara H, Cerami A. Advanced Glycosylation Endproducts: Role in Diabetic and Non-diabetic vascular disease. Drug Development Research 1994;32:77-89.
6. Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol 1992;23:1-34.
7. Brownlee M, Cerami A, Vlassara H. Advanced glycosylation endproducts in tissue and the biochemical basis of diabetic complications. N Engl J Med 1988;318:1315-21.
8. Cai W, Gao QD, Zhu L, Peppa M, He C, Vlassara H. Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 2002;8:337-46.
9. Brownlee M. Negative consequences of glycation. Metabolism 2000;49(suppl 1):9-13.
10. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001;44:129-46.
11. Gugliucci A. Glycation as the glucose link to diabetic complications. J Am Osteopath Assoc 2000;100:621-34.
12. Kado S, Nagata N. Circulating intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 1999;46:143-8.
13. Boulanger E, Wautier MP, Wautier JL et al. AGEs bind to mesothelial cells via RAGE and stimulate VCAM-1 expression. Kidney Int 2002;61:148-56.
14. Ceriello A, Falleti E, Motz E et al. Hyperglycemia-induced circulating ICAM-1 increase in diabetes mellitus: the possible role of oxidative stress. Horm Metab Res 1998;30:146-9.
15. Kunt T, Forst T, Harzer O et al. The influence of advanced glycation endproducts (AGE) on the expression of human endothelial adhesion molecules. Exp Clin Endocrinol Diabetes 1998;106:183-8.
16. Sengoelge G, Fodinger M, Skoupy S et al. Endothelial cell adhesion molecule and PMNL response to inflammatory stimuli and AGE-modified fibronectin. Kidney Int 1998;54:1637-51.
17. Smulders RA, Stehouwer CDA, Schalkwijk CG, Donker AJ, van Hinsbergh VW, TeKoppele JM. Distinct associations of HbA1c and the urinary excretion of pentosidine, an advanced glycosylation end-product, with markers of endothelial function in insulin-dependent diabetes mellitus. Thromb Haemost 1998;80:52-7.
18. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM- 1) expression and atheroma formation in normal rabbits. Mol Med 1995;1:447-56.
19. Wolffenbuttel BHR, Giordano D, Founds HW, Bucala R. Long-term assessment of glucose control by haemoglobin-AGE measurement. Lancet 1996;347:513-5.
20. Chiarelli F, De Martino M, Mezzetti A et al. Advanced glycation endproducts in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr 1999;134:486-91.
21. Leeuwenberg JF, Smeets EF, Neefjes JJ et al. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology 1992;77:543-9.
22. Kilhovd BK, Berg TJ, Birkeland KI, Thorsby P, Hanssen KF. Serum levels of advanced glycation endproducts are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 1999;22:1543-8.
23. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical Detection of Advanced Glycosylation Endproducts in vivo. J Biol Chem 1992;267:5133-8.
24. Kilhovd BK, Giardino I, Torjesen PA et al. Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes. Metabolism 2003;52:163-7.
25. Merbel NC, Mentink CJAI, Hendriks G, Wolffenbuttel BHR. Liquid chromatographic method for the quantitative determination of Ne-carboxymethyllysine in human plasma proteins. J Chromatogr B: Biomed Applic 2004;808:163-8.
26. Beisswenger PJ, Howell SK, Touchette AD, Lal S, Szwergold BS. Metformin reduces systemic methylglyoxal levels in type 2 diabetes. Diabetes 1999;48:198-202.
27. Scarpello JH. Improving survival with metformin: the evidence base today. Diabetes Metab 2003;29:6S36-6S43.
28. Wolffenbuttel BHR, Heine RJ. [Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications]. Ned Tijdschr Geneeskd 1999;143:1197-201.
29. Ruggiero-Lopez D, Howell S, Szwergold BS, Wiernsperger N, Beisswenger P. Metformin reduces methylglyoxal levels by formation of a stable condensation product (Triazepinone). Diabetes 2000;49(suppl 1):A124.
30. Leverve XM, Guigas B, Detaille D et al. Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 2003; 29(4 Pt 2):6S88-6S94.
31. Ouslimani N, Peynet J, Bonnefont-Rousselot D, Therond P, Legrand A, Beaudeux JL. Metformin decreases intracellular production of reactive oxygen species in aortic endothelial cells. Metabolism 2005;54:829-34.
32. Chang T, Wang R, Wu L. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic Biol Med 2005;38:286-93.
33. Ceriello A, Quagliaro L, Piconi L et al. Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 2004;53:701-10.
34. Berg TJ, Snorgaard O, Faber J et al. Serum levels of advanced glycation endproducts are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 1999;22:1186-90.
35. Meerwaldt R, Graaff R, Oomen PHN et al. Simple non-invasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004;47:1324-30.
36. Schalkwijk CG, Ligtvoet N, Twaalfhoven H et al. Amadori albumin in type 1 diabetic patients: correlation with markers of endothelial function, association with diabetic nephropathy, and localization in retinal capillaries. Diabetes 1999;48:2446-53.